Physician profile
Mychal Ross
NPI 1245873330
$1,150.94
in general payments reported to CMS, 2019-2025
17 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $188 · 2022: $106 · 2023: $171 · 2024: $272 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.30 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $247.90 | 2021-2025 | |
| Novo Nordisk INC | $236.18 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $137.85 | 2022-2025 | Otezla, Repatha, Prolia |
| Glaxosmithkline, LLC. | $132.16 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $85.75 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $37.76 | 2021 | |
| Merck Sharp & Dohme LLC | $36.76 | 2023-2025 | M-M-R II, Gardasil 9, Vaxneuvance |
| Pfizer INC. | $35.93 | 2025 | |
| Csl Behring | $28.83 | 2023 | Haegarda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.04 | 2021-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $26.51 | 2025 | |
| Medtronic, INC. | $24.52 | 2024 | Inpen Smart Insulin Delivery System |
| Esperion Therapeutics, INC. | $22.94 | 2021 | |
| Phathom Pharmaceuticals, INC. | $22.18 | 2025 | Voquezna |
| Astellas Pharma US INC | $18.22 | 2024 | Veozah |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $15.84 | 2025 | Natroba, Spinosad |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.57 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mychal Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.